Quest Diagnostics stock falls 1.81% and underperforms competitors

6 articles · Updated · MarketWatch · May 8

Shares closed at $187.39 as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average added 0.02% to 49,609.16.
Quest lagged peers including UnitedHealth, up 2.77%, Centene, up 1.78%, and IQVIA, up 0.04%, despite a broadly positive trading session.
The stock finished 12.23% below its 52-week high of $213.50 reached on 27 February, while trading volume of 760,243 was below its 50-day average.

As Quest raises guidance, is its stock drop a warning of underestimated regulatory risks ahead?

Can Quest's AI strategy outpace the financial threats from looming reimbursement cuts and stricter FDA rules?